Zocor Ad Targets Diabetics With Reference To Heart Protection Study
This article was originally published in The Tan Sheet
Executive Summary
A new TV ad campaign promoting Merck's Zocor (simvastatin) to diabetics closely follows the statin's switch to behind-the-counter status in the UK
You may also be interested in...
J&J/Merck Developing Mevacor 20 Mg As OTC For Moderate Risk Group
J&J/Merck's second try at an Rx-to-OTC switch for Mevacor (lovastatin) involves a 20 mg dose targeted at a moderate to intermediate risk group, according to VP-Regulatory & Scientific Affairs Edwin Hemwall, PhD
Non-Rx Zocor Will Be Available In UK Without Cholesterol Screen Requirement
Customers who present at UK pharmacies to purchase McNeil Europe's Zocor Heart-Pro (simvastatin 10 mg) without a prescription will need to disclose risk factors such as age and family history of heart disease, but not necessarily their cholesterol level, under a marketing plan cleared by the UK health agency
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC